Evidence Sprint

Illustrative decision brief

Tissue evidence or distribution imaging?

A fictional antibody program with enough budget for one follow-up study.

Decision owner
Sponsor development team
Program
Preclinical antibody for a solid tumor indication
Decision window
Before the next preclinical portfolio review

What is known

The program has an activity signal in a target-positive model. Its supporting expression data come from a small, selected tissue set. The team has yet to establish how well that set represents its proposed indication.

Options considered

StudyQuestion resolvedPriority
Independent tissue reviewHow well does the available expression evidence cover the intended tumor population?Prioritize
Distribution imagingWhere does the labeled candidate accumulate in the selected model?Defer
Repeat the activity studyIs the signal repeatable within the same model?Revisit if reproducibility is questioned

Recommendation and review condition

Review an independent tissue set first. For this program, evidence about the intended population is more likely to change the indication decision. Revisit imaging if expression is sufficiently consistent but delivery remains uncertain. If sample quality prevents a meaningful comparison, pause and reassess specimen feasibility.

Development decision remains with the sponsor.